Genetic Testing After 40: What Actually Changes Your Medicine, and What Just Sells Supplements

A saliva tube arrives in the mail, you spit, and three weeks later a dashboard tells you that you carry a variant "linked to" inflammation, slow detox, or suboptimal methylation. Then comes the upsell: a stack of methylated B-vitamins or a proprietary protocol "matched to your DNA."

It feels like the future of personalized medicine. Often, it is just marketing wearing a lab coat.

The honest version is more useful and more boring. A small number of genetic tests can genuinely reshape how you screen for disease, which drugs you take, and what you tell your siblings and children. A much larger number tell you almost nothing actionable. The skill, especially after 40 when screening decisions start to matter, is telling the two apart.

Established evidence: the tests that change real decisions

A genetic result earns its keep when a positive finding triggers a different, evidence-backed action. Three categories clear that bar today.

Hereditary cancer risk

This is the strongest case. Pathogenic variants in BRCA1 and BRCA2 (hereditary breast and ovarian cancer) and in the mismatch-repair genes behind Lynch syndrome don't just label you "high risk." They change the screening schedule, open the door to risk-reducing surgery, and can justify earlier and more frequent surveillance.

They also extend beyond you. Because these are inherited single-gene conditions, identifying one carrier lets relatives be tested — "cascade testing." A 30-year UK series found that this process generated close to one additional positive relative per index case and led to over a thousand risk-reducing operations (Manchester cohort, *Cancers*, 2021). Just as importantly, relatives who test negative can often step out of high-intensity screening, sparing them years of anxiety and false positives (UK centre review, *J Med Genet / PMC*, 2024).

Pharmacogenomics: predicting how you'll handle a drug

Some variants predict whether a medication will work or hurt you, and these are among the most concrete wins in all of genetics.

• **HLA-B\*57:01 and abacavir.** Carrying this allele dramatically raises the risk of a serious hypersensitivity reaction to the HIV drug abacavir. Screening before prescribing — and avoiding the drug in carriers — sharply reduces those reactions, which is why the FDA and other regulators put it directly on the label (Medical Genetics Summaries, NCBI Bookshelf).
• CYP2C19 and clopidogrel. People who poorly metabolize this common antiplatelet drug get less protection from it and face higher rates of heart attack and stroke. The American Heart Association supports genotype-guided testing in cardiovascular care (Testing.com overview).

The pattern is the key takeaway: a clear gene, a clear drug, a clear alternative action.

Emerging evidence: promising, not yet plug-and-play

Polygenic risk scores

Most common diseases — heart disease, type 2 diabetes — aren't driven by one gene but by thousands of small effects. Polygenic risk scores (PRS) try to sum those effects into a single number.

The signal is real but still maturing. Adding a coronary-artery-disease PRS to a standard clinical risk model modestly improves prediction, and it can be genuinely useful for reclassifying people whose 10-year risk sits in the ambiguous "intermediate" zone (*European Heart Journal*, 2024). The honest caveat: most scores were built largely in people of European ancestry, so they perform unevenly — and often worse — in other groups (*Nature Medicine*, 2023). A PRS today is a tiebreaker, not a verdict. If yours nudges a borderline statin or imaging decision, it's doing its job; if it promises to "know your destiny," it's overselling.

The underrated baseline: your family history

Here is the part the marketing skips. A carefully taken family history often captures inherited risk that a consumer DNA panel misses entirely — because it integrates every gene you inherited plus shared environment, expressed as actual disease in actual relatives.

For coronary artery disease, family history is an independent risk factor even after accounting for cholesterol, blood pressure, smoking, diabetes, and body weight. In the Framingham data, a positive parental history was associated with roughly a 29% increase in CAD risk, on par with several classic risk factors (Framingham Study, *American Heart Journal*, 1990). No spit kit required — just a few specific questions asked of the right relatives.

What's worth recording: which relatives had heart attacks, strokes, or cancers; at what age; and which cancers in particular. Early age of onset and clustering of the same disease are the signals clinicians act on.

Personal experimentation: a sane order of operations

This is where to label things clearly. The following is a reasonable self-directed framework, not medical advice — decisions about testing and screening belong with a clinician.

1. Build the family map first. It's free, it's high-yield, and it tells a genetic counselor where to actually look. Three generations, ages of diagnosis, specific diseases.
2. Test with a question, not curiosity. The value of any test depends on the decision it could change. "Should I start cancer screening earlier?" or "Will this drug work for me?" are good questions. "What do my genes say about me?" rarely produces an action.
3. Treat consumer panels as hypotheses, not diagnoses. Direct-to-consumer results can be incomplete or misclassified, and a flagged finding warrants confirmation in a clinical-grade lab with counseling before anyone acts on it (MedlinePlus: MTHFR gene test).
4. Be skeptical of variant-to-supplement pipelines. MTHFR is the textbook example: the common variants are carried by a large share of the population, yet major medical groups don't recommend routine MTHFR testing because a result rarely changes care — despite a thriving industry of "MTHFR protocols" (*J Clin Med* review, 2024). A variant being common and detectable is not the same as it being clinically meaningful.

The bottom line

Genetics has handed us a few genuinely powerful, decision-changing tools — hereditary cancer testing and pharmacogenomics chief among them — alongside a much larger cloud of findings that are interesting at best and monetized at worst. After 40, the move that beats almost any kit is the cheapest one: sit down, map your family's medical history in specifics, and bring that map to someone who can tell you which test, if any, would actually change what you do next. Test to answer a question. If a result wouldn't change a single decision, you don't need it — no matter how personalized it looks.

Sources